Preparing Investors for MDS' conversion from Canadian to US GAAP Filing
TORONTO, Jan. 25 /CNW/ - MDS Inc. (TSX: MDS; NYSE: MDZ), a leading
provider of products and services to the global life sciences markets, today
issued an MDS US GAAP Primer in anticipation of filing its 2007 year-end
financials and annual report for the first time in US GAAP on January 29,
This MDS US GAAP Primer is intended to prepare investors for MDS'
conversion from Canadian to US GAAP filing. The MDS US GAAP Primer provides an
overview of the relevant differences between US and Canadian GAAP affecting
MDS, including an explanation of the accounting, presentation and disclosure
differences and their impact on MDS financials.
The MDS US GAAP Primer is available on the MDS website at:
More details including a summary of significant accounting policies will
be available in the notes to the financial statements in the MDS 2007 Annual
Report to be filed on January 29, 2008. As additional support, MDS also
intends to make available on the MDS website:
- 2007 interim financial statements that have been restated to US GAAP;
- Canadian to US GAAP reconciliation tables for MDS and its business
About MDS Inc.
MDS Inc. is a global life sciences company that provides market-leading
products and services that our customers need for the development of drugs and
the diagnosis and treatment of disease. We are a leading global provider of
pharmaceutical contract research, medical isotopes for molecular imaging,
radiotherapeutics, and analytical instruments. MDS has more than 5,500 highly
skilled people in 28 countries. Find out more at www.mdsinc.com or by calling
1-888-MDS-7222, 24 hours a day.
For further information:
For further information: Sharon Mathers, Senior Vice-President, Investor
Relations and External Communications, MDS Inc., (416) 213-4721,